Teprotumumab for the Treatment of Active Thyroid Eye Disease.
N Engl J Med. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434.
N Engl J Med. 2020.
PMID: 31971679
Clinical Trial.